{"disease":{"id":"pd-l1-expression","name":"pd l1 expression"},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Advanced melanoma with tumour cell PD-L1 expression below 1%","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"relatlimab-rmbw","indication_name":"Advanced melanoma with tumour cell PD-L1 expression below 1%","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OPDUALAG","generic_name":"RELATLIMAB-RMBW","company_name":"BRISTOL MYERS SQUIBB","drug_phase":"marketed","molecular_target":"Lymphocyte activation gene 3 protein","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as a monotherapy in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as a monotherapy in adults and in combination with pembrolizumab in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (Tumor Proportion Score (TPS) ≥ 50%) as monotherapy (pembrolizumab in combination with pemetrexed and platinum (pemetrexed + platinum) in patients with a PD-L1 TPS ≥ 1% as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"opdualag","indication_name":"Advanced melanoma with tumour cell PD-L1 expression below 1%","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Opdualag","company_name":"Australian & New Zealand Children's Haematology/Oncology Group","drug_phase":"marketed","molecular_target":"Lymphocyte activation gene 3 protein","drug_class":"","quality_score":25,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":62,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07396259","title":"Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT05445843","title":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":95,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}